SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on regulatory guidance for ...

Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the identification of heteroaromatic ring compounds acting as membrane-associated tyrosine-and threonine-specific Cdc2-inhibitory ...